Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- First-Line Systemic Treatments of Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-Analysis.The Journal of urology · 2026Pooled it
- Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.Targeted oncology · 2026Pooled it
- Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.JCO precision oncology · 2026Trial
- PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.European urology open science · 2026Review
- Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer.The oncologist · 2026Article
- Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer.The oncologist · 2026Article
- Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review.Cancers · 2026Review
- Impact of the Nadir Androgen Receptor Signaling Inhibitor-Derived Integrative Response Model in Real-World Patients With Metastatic Castration-Sensitive Prostate Cancer.The Prostate · 2026Article
- Article
- Prostate- and metastases-directed radiotherapy in de novo low-volume metastatic prostate cancer.Clinical and translational radiation oncology · 2026Article
- Case Report: Fatal convergence of two confirmed and one radiologically suspected synchronous urological malignancies in a young patient: ultra-late clear cell renal cell carcinoma recurrence, contralateral renal tumor, and metastatic prostate cancer.Frontiers in oncology · 2026Article
- Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study From Vietnam.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThe CHAARTED trial investigated the long-term survival of patients with metastatic hormone-sensitive prostate cancer (HSPC) treated with androgen deprivation therapy (ADT) with or without docetaxel (Taxotere). This analysis focuses on 10-year overall survival (OS) stratified by disease volume and on-therapy prostate-specific antigen (PSA) levels at 6 months. PATIENTS AND
methodsOS was calculated using the Kaplan-Meier method from randomization to death or last known alive date. Patients were grouped based on baseline disease characteristics [high-volume (HV) or low-volume (LV)] and PSA levels at 6 months (<0.2 ng/ml versus ≥0.2 ng/ml). Multivariable Cox regression analysis was used to evaluate correlation of PSA nadir with OS adjusted for treatment arm, disease volume, Gleason score, and prior local therapy.
resultsOf 790 patients, 225 were without recorded death after a median follow-up of 10 years. The 10-year OS was 25.9% (ADT + docetaxel) versus 22.5% [ADT; hazard ratio (HR) 0.78, P = 0.004]. HV patients treated with docetaxel had significantly higher OS (20.9% versus 11.4%, P < 0.0001). PSA <0.2 ng/ml at 6 months was associated with improved median OS in both ADT + docetaxel (100.3 versus 45.4 months, P < 0.0001) and ADT (116.8 versus 31.8 months, P < 0.0001) arms. PSA nadir <0.2 ng/l at 6 months was an independent predictor of improved OS (HR 0.41, P < 0.0001) adjusting for disease volume, prior local therapy, Gleason score and treatment arm.
conclusionsLong-term follow-up confirms that ADT + docetaxel significantly improves OS in metastatic HSPC patients with HV disease. PSA nadir <0.2 ng/ml at 6 months is a strong prognostic marker for OS, supporting its use in response-adapted de-escalation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.